Relvar Ellipta inhalation powder

Relvar Ellipta is a medication used for the long-term treatment of asthma and chronic obstructive pulmonary disease (COPD). It is a combination drug containing fluticasone furoate and vilanterol. The Ellipta inhaler technology was developed through a collaboration between GlaxoSmithKline (GSK) and Innoviva (formerly Theravance).

The product is manufactured primarily in the United Kingdom at GSK's specialized respiratory manufacturing facilities. GSK, a global leader in respiratory health, owns the brand and is headquartered in London. The medication is distributed globally under various names (such as Breo Ellipta in the US) and is available in Brazil through GSK's local subsidiary.